Cancer treatments

Global Chemotherapy Induced Nausea & Vomiting Clinical Trials Report 2020: Analysis by Trial Status, Trial Phase, Sponsor Type, End Point Status, Region and Country

Saturday, April 4, 2020 - 12:15am

DUBLIN, April 3, 2020 /PRNewswire/ -- The "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 3, 2020 /PRNewswire/ -- The "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report provides an overview of Chemotherapy Induced Nausea and Vomiting Clinical trials scenario.
  • The report provides top line data relating to the clinical trials on Chemotherapy Induced Nausea and Vomiting.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today

Friday, April 3, 2020 - 5:06pm

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification.

Key Points: 
  • CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification.
  • These are conditions where the risk of death is extremely high, yet no effective treatments exist.
  • CytoSorb has been used in more than 80,000 human treatments to date.
  • For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter .

TCR² Therapeutics to Present at the Goldman Sachs Cell Therapy Day

Friday, April 3, 2020 - 12:00pm

CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Alfonso Quints Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics, will present an update on company progress during the panel Emergence of TCRs and Next-Generation Therapies at the Goldman Sachs Cell Therapy Day on April 6, 2020 at 2:00pm ET using a virtual platform.

Key Points: 
  • CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Alfonso Quints Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics, will present an update on company progress during the panel Emergence of TCRs and Next-Generation Therapies at the Goldman Sachs Cell Therapy Day on April 6, 2020 at 2:00pm ET using a virtual platform.
  • TCR2Therapeutics Inc.is a clinical-stage immunotherapy company developing the next generation of novel Tcell therapies for patients suffering from cancer.TCR2sproprietary T cell receptor (TCR) Fusion Construct Tcells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent ofhuman leukocyte antigens (HLA).
  • In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
  • The Companys lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

Cell Therapy Processing Market to Reach $12.06 Bn, Globally, by 2026 at 27.8% CAGR: Allied Market Research

Thursday, April 2, 2020 - 2:29pm

Increase in the incidence of cardiovascular diseases and surge in the demand for chimeric antigen receptor (CAR) cell therapy propel the global cell therapy processing market.

Key Points: 
  • Increase in the incidence of cardiovascular diseases and surge in the demand for chimeric antigen receptor (CAR) cell therapy propel the global cell therapy processing market.
  • Based on offering type, the products segment contributed to more than four-fifths of the total share of the global cell therapy processing market in 2018 and is expected to maintain its leadership position throughout the forecast period.
  • Based on application, the skeletal muscle segment accounted for the largest market share of the global cell therapy processing market in 2018, accounting for more than one-fifth of the total market share in 2018.
  • Moreover, Asia-Pacific is expected to maintain the highest CAGR of 29.0% from 2019 to 2026, owing to presence of huge patient base, increase in research and development expenditure, and surge in usage of cell therapy processing products.

Cell Therapy Processing Market to Reach $12.06 Bn, Globally, by 2026 at 27.8% CAGR: Allied Market Research

Thursday, April 2, 2020 - 2:25pm

Increase in the incidence of cardiovascular diseases and surge in the demand for chimeric antigen receptor (CAR) cell therapy propel the global cell therapy processing market.

Key Points: 
  • Increase in the incidence of cardiovascular diseases and surge in the demand for chimeric antigen receptor (CAR) cell therapy propel the global cell therapy processing market.
  • Based on offering type, the products segment contributed to more than four-fifths of the total share of the global cell therapy processing market in 2018 and is expected to maintain its leadership position throughout the forecast period.
  • Based on application, the skeletal muscle segment accounted for the largest market share of the global cell therapy processing market in 2018, accounting for more than one-fifth of the total market share in 2018.
  • Moreover, Asia-Pacific is expected to maintain the highest CAGR of 29.0% from 2019 to 2026, owing to presence of huge patient base, increase in research and development expenditure, and surge in usage of cell therapy processing products.

Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer

Thursday, April 2, 2020 - 1:00pm

Our initial data on the combination of PADCEV and pembrolizumab in previously untreated patients who could not receive cisplatin are encouraging.

Key Points: 
  • Our initial data on the combination of PADCEV and pembrolizumab in previously untreated patients who could not receive cisplatin are encouraging.
  • The EV-302 trial is evaluating the combination of PADCEV and pembrolizumab with or without chemotherapy versus chemotherapy alone in patients with previously untreated locally advanced or metastatic urothelial cancer.
  • PADCEV was approved under the FDAs Accelerated Approval Program based on tumor response rate.
  • Hyperglycemia occurred in patients treated with PADCEV, including death and diabetic ketoacidosis (DKA), in those with and without pre-existing diabetes mellitus.

Company Profile for Atara Biotherapeutics, Inc.

Thursday, April 2, 2020 - 1:33pm

Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.

Key Points: 
  • Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.
  • Ataras technology platform leverages research collaborations with leading academic institutions with the Companys scientific, clinical, regulatory and manufacturing expertise.
  • The Company was founded in 2012 and is co-located in South San Francisco and Southern California.
  • For additional information about the Company, please visit atarabio.com .

Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic

Thursday, April 2, 2020 - 1:30pm

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update in context of the COVID-19 (coronavirus) pandemic.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update in context of the COVID-19 (coronavirus) pandemic.
  • While this is an unprecedented time in history, Atara is working hard to ensure operational continuity to serve patients whose lives are affected by severe diseases, said Pascal Touchon, President and Chief Executive Officer of Atara Biotherapeutics.
  • Atara believes that it remains on track to initiate a tab-cel biologics license application (BLA) submission for patients with EBV+ PTLD in the second half of 2020.
  • Atara Biotherapeutics, Inc. ( @Atarabio ) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.

Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

Wednesday, April 1, 2020 - 9:15pm

Zymeworks will receive a payment under its collaboration with BeiGene as a result of the achievement of this development milestone.

Key Points: 
  • Zymeworks will receive a payment under its collaboration with BeiGene as a result of the achievement of this development milestone.
  • We look forward to the results of these trials, which have the potential to further expand the population of patients who may benefit from ZW25.
  • Arm one of the trial will evaluate the safety, tolerability, and preliminary antitumor activity of ZW25 in combination with docetaxel in patients with metastatic HER2positive breast cancer.
  • Zymeworks lead clinical candidate, ZW25, is a novel Azymetric bispecific antibody currently in Phase 2 clinical development.

Global Immune Checkpoint Inhibitors Market Outlook 2022

Wednesday, April 1, 2020 - 7:15pm

DUBLIN, April 1, 2020 /PRNewswire/ -- The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 1, 2020 /PRNewswire/ -- The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.
  • According to the report Global Immune Checkpoint Inhibitors Market Outlook 2022, the global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022.
  • In addition, the report also highlights various opportunities available for the growth of the global immune checkpoint inhibitors market.
  • On the basis of the type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.